Allergan Aesthetics to Present GLP-1 RA–Related Aesthetic Research at ASDS 2026
Key Takeaways
- Allergan Aesthetics will present 9 abstracts at ASDS 2026, including two Phase 4 studies evaluating aesthetic treatments in patients receiving GLP-1 RA–related medications for weight management.
- Research will examine patient satisfaction, psychosocial outcomes, facial appearance, and skin quality following multimodal aesthetic treatment.
- Additional presentations will address investigational trenibotulinumtoxinE, exosome-based skincare, and combination body-contouring procedures.
Allergan Aesthetics, an AbbVie company, will present 9 research abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, November 5-8 in San Diego, including studies examining aesthetic outcomes among patients receiving glucagon-like peptide-1 (GLP-1)–related medications for weight management.
The presentations will address facial appearance, skin quality, patient satisfaction, and psychosocial outcomes, alongside research involving neuromodulators, body contouring, and topical skincare products.
Phase 4 Studies Examine Aesthetic Outcomes Following Medical Weight Loss
Two Phase 4 studies will evaluate aesthetic treatments among patients undergoing medical weight loss. The first, HARMONY IN DIVERSITY, examines satisfaction with aesthetic appearance and psychosocial functioning following multimodal aesthetic treatment.
The second investigates overall facial appearance satisfaction and psychological outcomes following treatment with hyaluronic acid injectables.
Additional research will evaluate glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and onabotulinumtoxinA (BOTOX Cosmetic). The digital image analysis will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session on November 8.
Other abstracts will examine multimodal facial and neck treatments across diverse patient populations, including patient-reported outcomes. Presentations will also address a topical human fibroblast-derived exosome serum used independently and alongside procedures including radiofrequency microneedling, nonablative laser treatment, and microdermabrasion.
Another study will investigate whether treatment sequence affects outcomes and patient experience when combining cryolipolysis with electromagnetic muscle stimulation for abdominal contouring.
The company will also host an expert panel addressing changing consumer expectations, misconceptions about aesthetic treatments, and the relationship between medical weight loss and aesthetic care.
Source
Allergan Aesthetics. Allergan Aesthetics to present new research on aesthetic care following medical weight loss and evolving patient needs at ASDS 2026. PR Newswire. Published November 3, 2026. https://www.prnewswire.com/news-releases/allergan-aesthetics-to-present-new-research-on-aesthetic-care-following-medical-weight-loss-and-evolving-patient-needs-at-asds-2026-302927154.html